NCT07688200
Treatment Registry of Arrhythmias, Complications and Electrocardiograms in Arrhythmogenic CardioMyopathies
Not Yet Recruiting · Not specified · Policlinico Casilino ASL RMB · registry updated 2026-07-07
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
TRACE-ACM is a multicenter, retrospective, observational study of patients with arrhythmogenic cardiomyopathy who received an implantable cardioverter-defibrillator (ICD) and had documented ventricular tachyarrhythmias. The study aims to describe the prevalence and type of ICD-related complications, characterize ventricular arrhythmias documented by ICD electrograms and/or ECG recordings, and explore associations between clinical, device-related, and treatment-related factors and arrhythmic outcomes.
Inclusion
- Diagnosis of arrhythmogenic cardiomyopathy, including right-dominant arrhythmogenic right ventricular cardiomyopathy, biventricular arrhythmogenic cardiomyopathy, or left-dominant arrhythmogenic left ventricular cardiomyopathy.
- ICD implantation.
- Documented sustained ventricular tachyarrhythmia, including polymorphic ventricular tachycardia, ventricular fibrillation, or monomorphic ventricular tachycardia.
- Periodic clinical and ICD follow-up.
- Arrhythmia onset available from ICD electrograms and/or ECG recordings.
- ECG/EGM tracings available for analysis by the steering ECG committee.
Exclusion
- Incomplete ICD data or incomplete ICD follow-up.
- Significant coronary artery disease, defined as coronary plaque greater than 50% at coronary angiography or coronary computed tomography angiography.
- Primary valvular heart disease or congenital heart disease.
- Infiltrative or inflammatory cardiomyopathies, including sarcoidosis or amyloidosis.
- Previous exposure to therapies associated with cardiac toxicity, including chemotherapy.